抗肿瘤药物 270. 新型取代的 6-苯基-4H-呋喃并[3,2-c]吡喃-4-酮衍生物，作为有效且高选择性的抗乳腺癌药物。
Antitumor agents 270. Novel substituted 6-phenyl-4H-furo[3,2-c]pyran-4-one derivatives as potent and highly selective anti-breast cancer agents.
机构信息
Natural Products Research Laboratories, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599-7568, United States.
出版信息
Bioorg Med Chem. 2010 Jan 15;18(2):803-8. doi: 10.1016/j.bmc.2009.11.049. Epub 2009 Dec 2.
Abstract
6-Phenyl-4H-furo[3,2-c]pyran-4-one derivatives based on neo-tashinlactone (1) were synthesized and evaluated as novel anti-breast cancer agents. Compounds 10-13, 23, 25, and 27 showed potent inhibition against the SK-BR-3 breast cancer cell line. Importantly, 25 and 27 showed the highest cancer cell line selectivity, being approximately 100-250-fold more potent against SK-BR-3 (ED(50) 0.28 and 0.44microM, respectively) compared with other cancer cell lines tested. In addition, 25 displayed low cytotoxicity against normal breast cell lines 184A1 and MCF10A. Compounds 25 and 27 merit further investigation in our continuing program to generate and develop selective anti-breast cancer agents.
摘要
基于 neo-tashinlactone（1）的 6-苯基-4H-呋喃并[3,2-c]吡喃-4-酮衍生物被合成并评估为新型抗乳腺癌药物。化合物 10-13、23、25 和 27 对 SK-BR-3 乳腺癌细胞系表现出强烈的抑制作用。重要的是，25 和 27 对 SK-BR-3 的细胞系选择性最高，与测试的其他癌细胞系相比，其效力分别约高出 100-250 倍（ED（50）分别为 0.28 和 0.44μM）。此外，25 对正常乳腺细胞系 184A1 和 MCF10A 的细胞毒性较低。化合物 25 和 27 在我们继续开发和生成选择性抗乳腺癌药物的项目中值得进一步研究。
相似文献
1
Antitumor agents 270. Novel substituted 6-phenyl-4H-furo[3,2-c]pyran-4-one derivatives as potent and highly selective anti-breast cancer agents.抗肿瘤药物 270. 新型取代的 6-苯基-4H-呋喃并[3,2-c]吡喃-4-酮衍生物，作为有效且高选择性的抗乳腺癌药物。
Bioorg Med Chem. 2010 Jan 15;18(2):803-8. doi: 10.1016/j.bmc.2009.11.049. Epub 2009 Dec 2.
2
Antitumor agents. 272. Structure-activity relationships and in vivo selective anti-breast cancer activity of novel neo-tanshinlactone analogues.抗肿瘤药物。272. 新型 neo-tanshinlactone 类似物的结构-活性关系及体内选择性抗乳腺癌活性。
J Med Chem. 2010 Mar 11;53(5):2299-308. doi: 10.1021/jm1000858.
3
Antitumor agents. 254. Synthesis and biological evaluation of novel neo-tanshinlactone analogues as potent anti-breast cancer agents.抗肿瘤剂。254. 新型新丹参内酯类似物作为强效抗乳腺癌药物的合成与生物学评价。
J Med Chem. 2006 Sep 7;49(18):5631-4. doi: 10.1021/jm060184d.
4
Antitumor agents 269. Non-aromatic ring-A neotanshinlactone analog, TNO, as a new class of potent antitumor agents.抗肿瘤药物 269. 非芳环-A 丹参新酮类似物 TNO，作为一类新型强效抗肿瘤药物。
Bioorg Med Chem Lett. 2009 Nov 15;19(22):6289-92. doi: 10.1016/j.bmcl.2009.09.092. Epub 2009 Sep 29.
5
Antitumor agents. 266. Design, synthesis, and biological evaluation of novel 2-(furan-2-yl)naphthalen-1-ol derivatives as potent and selective antibreast cancer agents.抗肿瘤剂。266. 新型2-(呋喃-2-基)萘-1-醇衍生物作为强效和选择性抗乳腺癌药物的设计、合成及生物学评价
J Med Chem. 2009 Jun 11;52(11):3586-90. doi: 10.1021/jm9001567.
6
Development of Furo[2,3-b]quinoline Derivatives with Anti-Breast Cancer Property by Targeting Topoisomerase II.通过靶向拓扑异构酶II开发具有抗乳腺癌特性的呋喃并[2,3 - b]喹啉衍生物
Anticancer Agents Med Chem. 2021;21(12):1482-1489. doi: 10.2174/1871520620999201103201348.
7
Design and synthesis of novel tetrahydro-2H-Pyrano[3,2-c]pyridazin-3(6H)-one derivatives as potential anticancer agents.新型四氢-2H-吡喃并[3,2-c]哒嗪-3(6H)-酮衍生物的设计与合成及其作为潜在抗癌剂的研究。
Eur J Med Chem. 2010 Dec;45(12):5724-31. doi: 10.1016/j.ejmech.2010.09.029. Epub 2010 Sep 17.
8
Hybrids of 4-hydroxy derivatives of goniothalamin and piplartine bearing a diester or a 1,2,3-triazole linker as antiproliferative agents.作为抗增殖剂的戈尼辛和荜茇亭的 4-羟基衍生物的杂种，带有二酯或 1,2,3-三唑连接体。
Bioorg Chem. 2021 Nov;116:105292. doi: 10.1016/j.bioorg.2021.105292. Epub 2021 Aug 25.
9
Synthesis and Evaluation of 2-Naphthaleno trans-Stilbenes and Cyanostilbenes as Anticancer Agents.2-萘基反式二苯乙烯和氰基二苯乙烯作为抗癌剂的合成与评价
Anticancer Agents Med Chem. 2018;18(4):556-564. doi: 10.2174/1871521409666170412115703.
10
Design and Synthesis of (2,3-dichloro-4-(3-(substituted Phenyl)acryloyl) phenoxy) Substituted Carboxylic Acid as Potent Glutathione-s-transferase Inhibitors, Anti-breast-cancer Agents and Enhancing Therapeutic Efficacy of Anticancer Agents.作为强效谷胱甘肽 - S - 转移酶抑制剂、抗乳腺癌药物及增强抗癌药物治疗效果的（2,3 - 二氯 - 4 -（3 -（取代苯基）丙烯酰基）苯氧基）取代羧酸的设计与合成
Med Chem. 2025;21(4):319-330. doi: 10.2174/0115734064316508240911032442.
引用本文的文献
1
Synthesis of new condensed naphthoquinone, pyran and pyrimidine furancarboxylates.新型稠合萘醌、吡喃和嘧啶呋喃羧酸酯的合成。
Beilstein J Org Chem. 2025 Feb 12;21:340-347. doi: 10.3762/bjoc.21.24. eCollection 2025.
2
Anti-proliferative, Morphological and Molecular Docking Studies of New Thiophene Derivatives and their Strategy in Ionic Liquids Immobilized Reactions.新噻吩衍生物的抗增殖、形态和分子对接研究及其在离子液体固定化反应中的策略。
Anticancer Agents Med Chem. 2024;24(9):691-708. doi: 10.2174/0118715206262307231122104748.
3
Recent Progress of Research on Herbal Products Used in Traditional Chinese Medicine: the Herbs belonging to The Divine Husbandman's Herbal Foundation Canon ( Shén Nóng Běn Cǎo Jīng).中药本草典籍《神农本草经》中常用草药的研究进展
J Tradit Complement Med. 2012 Jan;2(1):6-26. doi: 10.1016/s2225-4110(16)30066-9.
4
In vitro cytotoxic potential of newly synthesized furo[3,2-c]pyran-4-one derivatives in cultured human lymphocytes.新型呋喃并[3,2-c]吡喃-4-酮衍生物在培养的人淋巴细胞中的体外细胞毒性潜力。
Cytotechnology. 2011 Aug;63(4):407-13. doi: 10.1007/s10616-011-9358-5. Epub 2011 May 15.
5
Antitumor agents 287. Substituted 4-amino-2H-pyran-2-one (APO) analogs reveal a new scaffold from neo-tanshinlactone with in vitro anticancer activity.抗肿瘤药物 287. 取代的 4-氨基-2H-吡喃-2-酮 (APO) 类似物揭示了一种新型支架，其来源于新型丹参酮，具有体外抗癌活性。
Bioorg Med Chem Lett. 2011 Apr 15;21(8):2341-4. doi: 10.1016/j.bmcl.2011.02.084. Epub 2011 Mar 21.
6
Antitumor agents 281. Design, synthesis, and biological activity of substituted 4-amino-7,8,9,10-tetrahydro-2H-benzo[h]chromen-2-one analogs (ATBO) as potent in vitro anticancer agents.抗肿瘤药物 281. 取代的 4-氨基-7,8,9,10-四氢-2H-苯并[h]色烯-2-酮类似物 (ATBO) 的设计、合成及体外抗肿瘤活性作为有效的抗肿瘤剂。
Bioorg Med Chem Lett. 2011 Jan 1;21(1):546-9. doi: 10.1016/j.bmcl.2010.10.074. Epub 2010 Nov 17.
7
Antitumor agents 278. 4-Amino-2H-benzo[h]chromen-2-one (ABO) analogs as potent in vitro anti-cancer agents.抗肿瘤药物 278. 4-氨基-2H-苯并[h]色烯-2-酮（ABO）类似物作为有效的体外抗癌剂。
Bioorg Med Chem Lett. 2010 Jul 15;20(14):4085-7. doi: 10.1016/j.bmcl.2010.05.079. Epub 2010 May 24.
本文引用的文献
1
Antitumor agents. 266. Design, synthesis, and biological evaluation of novel 2-(furan-2-yl)naphthalen-1-ol derivatives as potent and selective antibreast cancer agents.抗肿瘤剂。266. 新型2-(呋喃-2-基)萘-1-醇衍生物作为强效和选择性抗乳腺癌药物的设计、合成及生物学评价
J Med Chem. 2009 Jun 11;52(11):3586-90. doi: 10.1021/jm9001567.
2
Mitochondria-targeted chemotherapeutics: the rational design of gold(I) N-heterocyclic carbene complexes that are selectively toxic to cancer cells and target protein selenols in preference to thiols.线粒体靶向化疗药物：优先靶向蛋白质硒醇而非硫醇且对癌细胞具有选择性毒性的金（I）氮杂环卡宾配合物的合理设计。
J Am Chem Soc. 2008 Sep 24;130(38):12570-1. doi: 10.1021/ja804027j. Epub 2008 Aug 26.
3
A tissue-selective nonsteroidal progesterone receptor modulator: 7,9-difluoro-5-(3-methylcyclohex-2-enyl)-2,2,4-trimethyl-1,2-dihydrochromeno[3,4-f]quinoline.
J Med Chem. 2008 Jul 10;51(13):3696-9. doi: 10.1021/jm8004256. Epub 2008 Jun 14.
4
Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer.克服转移性乳腺癌化疗耐药的机制与策略
Cancer Treat Rev. 2008 Jun;34(4):378-90. doi: 10.1016/j.ctrv.2008.01.007. Epub 2008 Mar 25.
5
Structural simplification of bioactive natural products with multicomponent synthesis. 2. antiproliferative and antitubulin activities of pyrano[3,2-c]pyridones and pyrano[3,2-c]quinolones.通过多组分合成对生物活性天然产物进行结构简化。2. 吡喃并[3,2-c]吡啶酮和吡喃并[3,2-c]喹诺酮的抗增殖和抗微管蛋白活性。
J Med Chem. 2008 Apr 24;51(8):2561-70. doi: 10.1021/jm701499n. Epub 2008 Mar 25.
6
Cytotoxic simplified tubulysin analogues.细胞毒性简化的微管溶素类似物
J Med Chem. 2008 Mar 27;51(6):1530-3. doi: 10.1021/jm701321p. Epub 2008 Mar 4.
7
Plant-derived compounds in clinical trials.临床试验中的植物源化合物。
Drug Discov Today. 2008 Feb;13(3-4):161-71. doi: 10.1016/j.drudis.2007.10.010. Epub 2007 Nov 26.
8
Early breast cancer in the elderly: assessment and management considerations.老年早期乳腺癌：评估与管理考量
Drugs Aging. 2008;25(1):35-45. doi: 10.2165/00002512-200825010-00004.
9
Optimization of naphthalimide-imidazoacridone with potent antitumor activity leading to clinical candidate (HKH40A, RTA 502).具有强大抗肿瘤活性的萘酰亚胺-咪唑并吖啶酮的优化，通向临床候选药物（HKH40A，RTA 502）。
J Med Chem. 2007 Nov 15;50(23):5557-60. doi: 10.1021/jm7009777. Epub 2007 Oct 16.
10
Targeted cancer therapy: conferring specificity to cytotoxic drugs.靶向癌症治疗：赋予细胞毒性药物特异性。
Acc Chem Res. 2008 Jan;41(1):98-107. doi: 10.1021/ar700108g. Epub 2007 Aug 18.
Zotero 插件